Pure or dominant NEPC phenotypes, compared to the more common prostatic adenocarcinoma, often have visceral metastases, lytic bone lesions, relatively low serum prostate-specific antigen (PSA) levels, resists to castration, and could response to platinum-based chemotherapy [7]. The gene discussed is KLK3; the disease is prostate adenocarcinoma.